SCHEMBL7249266

SCHEMBL7249266

CCCC(=O)Oc1c(OCC)cccc1OCC1N(C)C(=O)c2ccccc2N1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TP53 P04637 1/20 0.37
HTR1A P08908 2/20 0.35
DRD2 P14416 2/20 0.35
HTR2A P28223 2/20 0.35
DRD1 P21728 1/20 0.35
CES1 P23141 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
HTR7 P34969 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7775208 0.75 ALDH1A1 (0.41) PKMALDH1A1MAPTLMNAKDM4E
SCHEMBL7770152 0.74 KMT2A (0.36) PKMALDH1A1MAPTLMNAKDM4E
SCHEMBL7775275 0.71 KMT2A (0.53) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL22141048 0.69 KMT2A (0.50) ALDH1A1MAPTLMNAKDM4EHTT
SCHEMBL15558032 0.69 KDM4E (0.56) KDM4EDRD2HTR2ADRD1MEN1
SCHEMBL15548183 0.68 POLM (0.53) KDM4EHTR2ADRD1MEN1KMT2A
SCHEMBL7250215 0.67 PPARG (0.56)
SCHEMBL28794439 0.67 NPC1 (0.52) PKMALDH1A1MAPTKDM4EHTT
SCHEMBL15557849 0.67 POLM (0.55) KDM4EMEN1KMT2APOLMPOLK
SCHEMBL15548325 0.67 POLM (0.55) KDM4EMEN1KMT2APOLMPOLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664411-B2 Beta-aryl/alpha-oxysubstituted alkylcarboxylic acids of 4-oxo-or thiocarbonylchromenes or thiochromenes; antiobesity, -cholesterol - diabetic agents; agonists of peroxisome proliferator activated receptors; kidney disorders DR. REDDY'S LABORATORIES LIMITED (IN) 2003-12-16 US disclosed
US-20010027198-A1 Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC. 2001-10-04 US disclosed
EP-1124807-A1 NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 2001-08-22 EP disclosed
WO-1999016758-A1 NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027198-A1 Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them CYP11B1, CYP46A1, CYP51A1 PKM 646/4885ALDH1A1 1511/4885MAPT 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.